A Phase Ⅲ Study of Hemay022 in Combination With AI In Advanced Breast Cancer

NCT06313983 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

339

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Hemay022+AI
DRUG: Lapatinib+Capecitabine

Sponsor

Tianjin Hemay Pharmaceutical Co., Ltd